PatientsVille.com LogoPatientsVille.com

Critical Limb Ischemia | Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia

Critical Limb Ischemia research study

What is the primary objective of this study?

The hypothesis behind the trial is the concept that Pregabalin is effective in reducing pain at rest in lower limb ischemia, and the study evaluates active treatment or placebo added to the regular pain regimens for these patients.

Who is eligible to participate?

Inclusion Criteria: - Rest pain, gangrene or ulcers located below the patella for a duration of at least two weeks (either one of these criteria are sufficient). - One measurement of: Ankle blood pressure(ABP) <70 mm Hg, an toe blood pressure(TBP) <50, or a TcPO2<45 mm Hg, or an ankle/brachial pressure index <0.7 (either one of these criteria are sufficient). - Informed consent obtained Exclusion Criteria: - Age < 55 years - Women of childbearing potential - Patients already medicating with Pregabalin or Gabapentin - Creatinine clearance <30ml/min - Amputation necessary within two weeks - Revascularization necessary within two weeks (open vascular surgery or endovascular) - A medical history of clear dizziness - NYHA class IV heart failure - Known hypotension, or having a systolic arm blood pressure <120 mm Hg (two consecutive measurements with the patient lying supine) - Simultaneous or previous (within 30 days prior to study entry participation in a clinical study using experimental drugs or devices - Mental condition making the subject unable to understand the concepts and risk of the study - Known allergies against pregabalin

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Critical Limb Ischemia

Arterial Occlusive Disease

Pain

Ischemia

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:pregabalinCapsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.

Drug:placeboCapsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

AActive intervention with pregabalin

Bplacebo arm with capsule Lyrica Placebo

Study Status

Terminated

Start Date: June 2006

Completed Date: July 2015

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome: Reduction in Rating Scale (RS) pain compared to baseline. RS Pain will be assessed at 7, 14 days for all participants and after 28 and 56 days for patients continuing the extended phase of study.

Secondary Outcome: Improvement in the Short Form 36 (SF-36) parameter "bodily pain".

Study sponsors, principal investigator, and references

Principal Investigator: Eric Wahlberg, MD. PhD

Lead Sponsor: Karolinska Institutet

Collaborator: Karolinska University Hospital

More information:https://clinicaltrials.gov/show/NCT00403780

Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, Visentin M, Gorni G, Martini C, Tirelli W, Barbieri M, De Conno F. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004 Jul 15;22(14):2909-17.

Discuss Lyrica